Stockreport

Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas

ADURO BIOTECH  (ADRO) 
Last aduro biotech earnings: 3/9 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aduro.com
PDF BERKELEY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, ann [Read more]